Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Hazot Yohan
 2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2018		 3. Issuer Name and Ticker or Trading Symbol
Foamix Pharmaceuticals Ltd. [FOMX]
(Last)
(First)
(Middle)
C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP Pharmaceutical Development
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

REHOVOT, L3 7670402		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Ordinary Shares 6,184
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options   (1) 02/01/2020 Ordinary Shares 6,125 $ 1.92 D  
Options   (2) 03/31/2024 Ordinary Shares 6,250 $ 1.92 D  
Options   (3) 01/15/2025 Ordinary Shares 18,000 $ 6.77 D  
Options   (4) 11/10/2025 Ordinary Shares 42,793 $ 7.13 D  
Options   (5) 03/01/2026 Ordinary Shares 60,000 $ 6.34 D  
Options   (6) 01/01/2027 Ordinary Shares 54,899 $ 10.31 D  
Restricted Share Units   (7)   (7) Ordinary Shares 2,816 $ 0 D  
Restricted Share Units   (8)   (8) Ordinary Shares 18,300 $ 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Hazot Yohan
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLZMAN STREET
REHOVOT, L3 7670402		       VP Pharmaceutical Development  

Signatures

/s/ Ilan Hadar as attorney-in-fact for Yohan Hazot 01/11/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The Options vested over a period of four years from February 2, 2010 (20% on such date and 5% every three months thereafter) and ending February 2, 2014
(2) The Options vest over a period of four years from March 31, 2014 (20% on such date and 5% every three months thereafter) and ending March 31, 2018
(3) The Options vest over a period of four years from January 15, 2015 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending January 15, 2019
(4) The Options vest over a period of four years from November 10, 2015 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending November 10, 2019
(5) The Options vest over a period of four years from March 1, 2016 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending March 1, 2020
(6) The Options vest over a period of four years from January 1, 2017 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending January 1, 2021
(7) The Restricted Share Units vest in equal installments every three months over the vesting period beginning October 15, 2017 ending January 15, 2019
(8) The Restricted Share Units vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021
 
Remarks:
The Reporting Person is filing this form in connection with the Issuer's transition from a foreign private issuer to a domestic issuer, effective January 1, 2018. Exhibit List: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.